Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules

Akihiro Mouri, Taku Nagai, Daisuke Ibi, Kiyofumi Yamada

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Schizophrenia is a severe and common psychiatric disease with a lifetime prevalence of 0.5% to 1% globally. Because of limitations of the experimental approach in humans, valid animal models are essential in the effort to identify novel therapeutics for schizophrenia. In most animal models of schizophrenia, second generation antipsychotic drugs are reported to be effective in ameliorating behavioral abnormalities, while clinical evidence indicates that some of the patients are resistant to the antipsychotic drug therapy. Accordingly, animal models of antipsychotic drug-resistant schizophrenia are needed for screening of novel agents that may be more effective than the existing antipsychotic drugs. Furthermore, utilization of appropriate behavioral tasks with reference to human testing is essential to facilitate the development of novel pharmacotherapeutic approaches for the treatment in schizophrenia. Experimental data suggest that there are different types of potential candidate molecules as novel antipsychotic drugs with some therapeutic effects on negative symptoms and cognitive deficits in schizophrenia. It is proposed that to develop novel antipsychotic drugs the efficacy of potential candidate molecules should be evaluated using animal models for treatment-resistant schizophrenia with appropriate behavioral tasks in reference to human testing.

Original languageEnglish
Pages (from-to)61-74
Number of pages14
JournalNeurobiology of Disease
Volume53
DOIs
Publication statusPublished - 01-05-2013

Fingerprint

Schizophrenia
Antipsychotic Agents
Animal Models
Pharmacology
Neurobehavioral Manifestations
Therapeutic Uses
Psychiatry
Therapeutics
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Neurology

Cite this

@article{2a0ab21b7a9742f5a2568008bc73bed7,
title = "Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules",
abstract = "Schizophrenia is a severe and common psychiatric disease with a lifetime prevalence of 0.5{\%} to 1{\%} globally. Because of limitations of the experimental approach in humans, valid animal models are essential in the effort to identify novel therapeutics for schizophrenia. In most animal models of schizophrenia, second generation antipsychotic drugs are reported to be effective in ameliorating behavioral abnormalities, while clinical evidence indicates that some of the patients are resistant to the antipsychotic drug therapy. Accordingly, animal models of antipsychotic drug-resistant schizophrenia are needed for screening of novel agents that may be more effective than the existing antipsychotic drugs. Furthermore, utilization of appropriate behavioral tasks with reference to human testing is essential to facilitate the development of novel pharmacotherapeutic approaches for the treatment in schizophrenia. Experimental data suggest that there are different types of potential candidate molecules as novel antipsychotic drugs with some therapeutic effects on negative symptoms and cognitive deficits in schizophrenia. It is proposed that to develop novel antipsychotic drugs the efficacy of potential candidate molecules should be evaluated using animal models for treatment-resistant schizophrenia with appropriate behavioral tasks in reference to human testing.",
author = "Akihiro Mouri and Taku Nagai and Daisuke Ibi and Kiyofumi Yamada",
year = "2013",
month = "5",
day = "1",
doi = "10.1016/j.nbd.2012.10.025",
language = "English",
volume = "53",
pages = "61--74",
journal = "Neurobiology of Disease",
issn = "0969-9961",
publisher = "Academic Press Inc.",

}

Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules. / Mouri, Akihiro; Nagai, Taku; Ibi, Daisuke; Yamada, Kiyofumi.

In: Neurobiology of Disease, Vol. 53, 01.05.2013, p. 61-74.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules

AU - Mouri, Akihiro

AU - Nagai, Taku

AU - Ibi, Daisuke

AU - Yamada, Kiyofumi

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Schizophrenia is a severe and common psychiatric disease with a lifetime prevalence of 0.5% to 1% globally. Because of limitations of the experimental approach in humans, valid animal models are essential in the effort to identify novel therapeutics for schizophrenia. In most animal models of schizophrenia, second generation antipsychotic drugs are reported to be effective in ameliorating behavioral abnormalities, while clinical evidence indicates that some of the patients are resistant to the antipsychotic drug therapy. Accordingly, animal models of antipsychotic drug-resistant schizophrenia are needed for screening of novel agents that may be more effective than the existing antipsychotic drugs. Furthermore, utilization of appropriate behavioral tasks with reference to human testing is essential to facilitate the development of novel pharmacotherapeutic approaches for the treatment in schizophrenia. Experimental data suggest that there are different types of potential candidate molecules as novel antipsychotic drugs with some therapeutic effects on negative symptoms and cognitive deficits in schizophrenia. It is proposed that to develop novel antipsychotic drugs the efficacy of potential candidate molecules should be evaluated using animal models for treatment-resistant schizophrenia with appropriate behavioral tasks in reference to human testing.

AB - Schizophrenia is a severe and common psychiatric disease with a lifetime prevalence of 0.5% to 1% globally. Because of limitations of the experimental approach in humans, valid animal models are essential in the effort to identify novel therapeutics for schizophrenia. In most animal models of schizophrenia, second generation antipsychotic drugs are reported to be effective in ameliorating behavioral abnormalities, while clinical evidence indicates that some of the patients are resistant to the antipsychotic drug therapy. Accordingly, animal models of antipsychotic drug-resistant schizophrenia are needed for screening of novel agents that may be more effective than the existing antipsychotic drugs. Furthermore, utilization of appropriate behavioral tasks with reference to human testing is essential to facilitate the development of novel pharmacotherapeutic approaches for the treatment in schizophrenia. Experimental data suggest that there are different types of potential candidate molecules as novel antipsychotic drugs with some therapeutic effects on negative symptoms and cognitive deficits in schizophrenia. It is proposed that to develop novel antipsychotic drugs the efficacy of potential candidate molecules should be evaluated using animal models for treatment-resistant schizophrenia with appropriate behavioral tasks in reference to human testing.

UR - http://www.scopus.com/inward/record.url?scp=84875109921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875109921&partnerID=8YFLogxK

U2 - 10.1016/j.nbd.2012.10.025

DO - 10.1016/j.nbd.2012.10.025

M3 - Review article

C2 - 23142533

AN - SCOPUS:84875109921

VL - 53

SP - 61

EP - 74

JO - Neurobiology of Disease

JF - Neurobiology of Disease

SN - 0969-9961

ER -